PDF(Pubmed)
Abstract：
The global nonprofit organization PATH hosted the third Vaccines Against Shigella and Enterotoxigenic Escherichia coli (VASE) Conference in Washington, DC, on November 29 to December 1, 2022. With a combination of plenary sessions and posters, keynote presentations, and breakout workshops, the 2022 VASE Conference featured key updates on research related to the development of vaccines against neglected diarrheal pathogens including Shigella, enterotoxigenic Escherichia coli (ETEC), Campylobacter, and Salmonella. The presentations and discussions highlighted the significant impact of these diarrheal pathogens, particularly on the health of infants and young children in low- and middle-income countries, reflecting the urgent need for the development and licensure of new enteric vaccines. Oral and poster presentations at the VASE Conference explored a range of topics, including: the global burden and clinical presentation of disease, epidemiology, and the impact of interventions; the assessment of the value of vaccines against enteric pathogens; preclinical evaluations of vaccine candidates and models of enteric diseases; vaccine candidates in clinical trials and human challenge models; host parameters and genomics that predict responses to infection and disease; the application of new omics technologies for characterization of emerging pathogens and host responses; novel adjuvants, vaccine delivery platforms, and immunization strategies; and strategies for combination/co-administered vaccines. The conference agenda also featured ten breakout workshop sessions on topics of importance to the enteric vaccine field, which are summarized separately. This article reviews key points and highlighted research presented in each of the plenary conference sessions and poster presentations at the 2022 VASE Conference.
摘要：
全球非营利组织PATH在华盛顿举办了第三次针对志贺氏菌和肠毒素大肠杆菌（VASE）疫苗会议，DC,2022年11月29日至12月1日。结合全体会议和海报，主题演讲，和突破性研讨会，2022年VASE会议对与开发包括志贺氏菌在内的被忽视腹泻病原体疫苗相关的研究进行了关键更新，产肠毒素大肠杆菌（ETEC），弯曲杆菌,还有沙门氏菌.演讲和讨论强调了这些腹泻病原体的重大影响，特别是低收入和中等收入国家的婴幼儿健康，反映出迫切需要开发和获得新的肠溶疫苗。在VASE会议上的口头和海报介绍探讨了一系列主题，包括：疾病的全球负担和临床表现，流行病学,以及干预措施的影响；评估针对肠道病原体的疫苗的价值；肠道疾病候选疫苗和模型的临床前评估；临床试验和人类攻击模型中的候选疫苗；预测感染和疾病反应的宿主参数和基因组学；应用新的组学技术表征新兴病原体和宿主反应；新型佐剂，疫苗输送平台，和免疫策略；以及联合/共同施用疫苗的策略。会议议程还包括十个分组研讨会，讨论对肠疫苗领域重要的主题，分别汇总。本文回顾了在2022年VASE会议的每次全体会议和海报演示中提出的要点和重点研究。
